2024-03-28T23:03:38Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/138172022-03-26T02:00:20Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
Bai, Xilian
author
Borrow, Ray
author
Bukovski, Suzana
author
Caugant, Dominique A
author
Culic, Davor
author
Delic, Snezana
author
Dinleyici, Ener Cagri
author
Eloshvili, Medeia
author
Erdősi, Tímea
author
Galajeva, Jelena
author
Křížová, Pavla
author
Lucidarme, Jay
author
Mironov, Konstantin
author
Nurmatov, Zuridin
author
Pana, Marina
author
Rahimov, Erkin
author
Savrasova, Larisa
author
Skoczyńska, Anna
author
Smith, Vinny
author
Taha, Muhamed-Kheir
author
Titov, Leonid
author
Vazquez-Moreno, Julio Alberto
author
Yeraliyeva, Lyazzat
author
2019-12
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.
J Infect. 2019 Dec;79(6):528-541.
http://hdl.handle.net/20.500.12105/13817
31682877
10.1016/j.jinf.2019.10.018
1532-2742
The Journal of Infection
Antibiotic resistance
Bacterial meningitis
Conjugate vaccine
Eastern Europe
High-risk groups
Immunization program
Meningococcal disease
Neisseria meningitidis
Polysaccharide vaccine
Refugees
Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe